The 30th International Symposium on Infections in the Critically Ill Patient (ISICIP) takes place in Barcelona on October 29 and 30, 2026. Estor, together with its partner Direx, supports the session “Adjunctive Therapies in Sepsis: Polymyxin B Hemoadsorption (PMX-HA)”, scheduled for Thursday, October 29.
ICARE 2026, the 80th National Congress of the Italian Society of Anaesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI), takes place in Milan from October 22 to 24, 2026. Estor is a partner of SIAARTI and ICARE and supports the sponsored session “Advanced Extracorporeal Therapies in Sepsis”, scheduled for Thursday, October 22.
ESICM LIVES 2026 takes place in Lisbon from October 10 to 14, 2026. Estor, together with TORAY, is a partner of ESICM. Visit us at our booth and enjoy the symposium “Advanced Extracorporeal Blood Purification in Critical Care”, scheduled for Wednesday, October 14, from 12:45 to 13:45 in Auditorium 2.
From June 17–19, Berlin will host the 57th Joint Annual Meeting of the German Society of Internal Intensive Care and Emergency Medicine (DGIIN) and the Austrian Society of Internal and General Intensive Care and Emergency Medicine (ÖGIAIN), one of the most important scientific events for intensivists and acute care specialists in the German-speaking world.
We are pleased to support the industry-sponsored symposium: “Endotoxic (Septic) Shock and Polymyxin B HemoAdsorption: why and when”, which will take place on Thursday, June 18, from 13:00 to 13:30.
The 44th VICENZA COURSE on AKI-CRRT-EBPT and Critical Care Nephrology (June 16–18, 2026) is fast approaching, bringing together leading international experts in Critical Care Nephrology, extracorporeal therapies, and organ support. On June 16 at 14:00, we are proud to support the Meet the Experts session “Polymyxin B Hemoadsorption: translating evidence into practice in Endotoxic Septic Shock”.
We will once again participate in the 37th edition of SMART Meeting Anesthesia Resuscitation Intensive Care, taking place from May 27 to 29, 2026, at Allianz MiCo, Milan.
As a partner of the congress, we will support two scientific sessions focused on extracorporeal organ support and endotoxic septic shock, with international experts discussing some of the most relevant challenges in intensive care medicine. We will also be present throughout the congress at our exhibition stand, where visitors can meet our team and learn more about our technologies and clinical solutions for critical care.
The TIGRIS trial results have been published in The Lancet Respiratory Medicine. In patients with endotoxic septic shock, Polymyxin B Hemoadsorption is associated with a high probability of lower mortality at 28 and 90 days. The Tigris trial shows a clinically meaningful signal of reduced mortality with polymyxin B in patients with ESS, alongside an acceptable safety profile.
ESTOR has obtained ISO 13485 certification, the international reference standard for quality management systems in the medical device sector. This achievement is a concrete recognition of the company’s ongoing commitment to safety, regulatory compliance, and the high performance of its products, further confirming its position as a reliable and innovative partner in the medical field.
Positive topline results from the Tigris trial have just been announced. This phase 3 follow-on sponsored study evaluates the use of Polymyxin B Hemoadsorption (“PMX” – Toray Medical Inc, Tokyo) in a randomized clinical trial of adults treated for Endotoxic Septic Shock (ESS) selected using the Endotoxin Activity Assay (EAA – Spectral Medical Inc., Toronto).